SHEAR INSIGHTS

September 7, 2018

HemoShear Invited to Share Expertise at 3D Modeling Conference

HemoShear Therapeutics was recently invited to present the company's groundbreaking platform at the Predict: 3D Models Conference on Enhancing the Predictive Confidence of Models Based Discovery and Development. The conference recognizes the pharmaceutical industry's growing interest in advanced biological systems to unmask novel disease targets, identify potential safety issues, and improve probability of successful drug R&D. The conference was attended by developers of advanced disease model systems and pharma leaders in drug discovery.

HemoShear's Head of Innovation Brian Wamhoff, PhD, showcased the ability of the company's REVEAL-Tx platform to create physiological disease models for drug discovery. His talk focused on leveraging HemoShear's non-alcoholic steatohepatitis (NASH) and liver rare disease models to interrogate disease pathways and identify novel therapeutic targets. As an industry thought leader, Dr. Wamhoff was also invited to host a roundtable to debate tissue-based vs. animal models, as well as concepts for 3D model validation.

"There are a number of academic and business organizations working on human-relevant, more predictive models of organ and disease biology," says Dr. Wamhoff. "I am proud that HemoShear has been recognized as a pioneer in this rapidly developing field, having published extensively and advanced the cutting edge by applying our technology to identify novel approaches to diseases with high unmet need."

HemoShear is utilizing its REVEAL-Tx platform to discover drugs to treat children's rare metabolic diseases. The company is also partnering with other pharmaceutical companies to discover new drug targets, including collaborating with Takeda Pharmaceuticals to identify innovative approaches to treat NASH fibrosis, a fast growing global disease.

HEMOSHEAR THERAPEUTICS

HemoShear Therapeutics discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need.